摘要
目的:观察尤瑞克林治疗急性脑梗死患者的疗效及安全性。方法:选择急性脑梗死患者106例,随机分成治疗组(56例)和对照组(50例)。对照组患者给予脱水、拜阿司匹林、阿托伐他汀钙片、依达拉奉、丹参多酚酸盐等基础治疗;治疗组患者在对照组基础上加用尤瑞克林治疗。比较两组患者的疗效及安全性。结果:治疗组患者的神经功能缺失评分、残障水平评分均低于对照组;总有效率高于对照组;不良反应发生率为5.4%。结论:在基础治疗的基础上,采用尤瑞克林治疗急性脑梗死患者的疗效优于单纯基础治疗。
Objective To investigate clinical curative effects and safety of Urinary Kallidinogenase in treatment of acute cere-bral infarction. Methods: 106 cases of acute cerebral infarction patients were randomly divided into treatment group ( n = 56 ) and con-trol group (n = 50). Both groups were given the basic treatment of dehydration, Aspirin enteric coated tablets, Atorvastatin calcium tablets, Edaravone, Salvianolate and the like; besides, Urinary Kallidinogenase was additionally given to the treatment group. The effects and safety of the two groups were compared. Results : The neurological deficit score and disability level score of treatment group were lower than those of control group; however, the total effective rate was higher than that of control group. The adverse reaction rate of treatment group was 5.4%. Conclusions: Urinary Kallidinogenase based on the basic treatment is more efficacious for acute cere-bral infarction than single basic treatment.
作者
蒋春
王思鸿
张矿梅
李刚
翁红霞
栾丹萍
吴东青
JIANG Chun WANG Sihong ZHANG Kuangmei LI Gang WENG Hongxia LUAN Danping WU Dongqing(The Third People's Hospital of Changzhou City, Changzhou Jiangsu 213001, China)
出处
《中国民康医学》
2016年第19期10-11,14,共3页
Medical Journal of Chinese People’s Health
关键词
尤瑞克林
急性脑梗死
临床疗效
Urinary Kallidinogenase
Acute cerebral infarction
Clinical effect